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onizes angiogenesis by inhibiting the biological function of vascular endothelial growth factor
(VEGF). Immature dendritic cells (imDCs) express high levels of sVEGFR1 during development
and are antiangiogenic. This study aimed to investigate the changes in VEGFR1, sVEGFR1, and
VEGF levels during the development of imDCs and explore the underlying signaling mecha-
nisms.
Methods: To model the differentiation of imDCs from monocytes, RAW264.7 cells, a murine
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receptor-1and 40 ng/mL) and/or by granulocyte-macrophage colony-stimulating factor (GM-CSF; 10 ng/mL,
20 ng/mL, and 50 ng/mL) and/or pretreated by the p38 inhibitor SB203580. The levels of VEGFR1,
sVEGFR1, and VEGFwere detected by reverse transcription polymerase chain reaction (RT-PCR),
Western blot, and enzyme-linked immunosorbent assay (ELISA).
Results: IL-4 increased the VEGFR1 mRNA and sVEGFR1 levels in RAW264.7 (p < 0.05). This in-
creasewas inhibited by SB203580. Granulocyte-macrophage colony-stimulating factor increased
the sVEGFR1 levels, but it had no significant effect on VEGFR1 mRNA levels. SB203580 decreased
the expression of VEGFR1mRNA induced byGM-CSF,whereas sVEGFR1was unaffected. IL-4 had a
greater effect on sVEGFR1 levels, compared to GM-CSF.
Conclusion: IL-4 and GM-CSF increased sVEGFR1 levels, but did not significantly effect VEGF
expression, and led to the antiangiogenesis properties ofmonocytes. p38 Mitogen-activated pro-
tein kinase signaling has an important role in the process.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The onset of many diseases such as cancer, atherosclerosis,
retinopathy, arthritis, and especially inflammation is
because of an imbalance in proangiogenesis and anti-
angiogenesis.1 Vascular endothelial growth factor and its
receptors VEGF receptor-1 (VEGFR1) and VEGF receptor-2
(VEGFR2) have a crucial role in angiogenesis disorders.2e4
Vascular endothelial growth factor promotes the survival,
migration, and proliferation of endothelial cells and in-
creases the vascular permeability of vessels.5,6 In endo-
thelial cells, VEGFR2 is the dominant mediator of
proangiogenesis. However, VEGFR1 is an antiangiogenic
factor because it sequesters VEGF from binding to VEGFR2.7
Soluble VEGFR1 (sVEGFR1) is an about 110 kDa splice
variant of 180 kDa of the membrane-spanning VEGFR1 that
lacks the transmembrane region.5,8 Soluble VEGFR1 se-
questers VEGF ligands, inhibits VEGF-mediated activation
of proangiogenic receptors, and heterodimerizes with full-
length vascular endothelial growth factor receptor
(VEGFR) monomers to render the receptor dimer inac-
tive.8,9 Therefore, sVEGFR1 is a promising biomarker and
therapeutic target for angiogenesis diseases.10e12
Dendritic cells (DCs) originate from myeloid precursors
and are the major antigen-presenting cells in the human
body. After antigen presentation, myeloid precursors
develop into immature dendritic cells (imDCs). With
continuous stimulation, imDCs mature into DCs and migrate
to the lymph nodes where the DCs present the antigens to
naı¨ve T cells.13,14 It has been postulated that cross-talk
between endothelial cells and immune cells may regulate
angiogenesis. For example, the VEGFR1 on monocytic and
dendritic immune cells15 is responsible for relaying VEGF
signals.16 In addition, when monocytes differentiate into
imDCs, they express costimulatory molecules such as CD1a,
CD86, and endothelial cell markers such as Willebrand
factor, vascular endothelial-cadherin, and VEGFR-1.17
Furthermore, imDCs develop into endothelial-like cells
when stimulated with VEGF, basic fibroblast growth factor,
and insulin-like growth factor 1. Blocking VEGFR1 inhibits
the maturation of lung DCs and their migration into the
lung-draining lymph nodes.18 Furthermore, the secretion ofsVEGFR1 induced by DCs increases the activity of DCs and
improves the survival of animals with tumors.19 These data
provide evidence that DCs are involved in angiogenesis.20,21
Because natural DCs are difficult to obtain in vivo and
exist only transiently in vitro, large-scale imDCs are ob-
tained by inducing monocytes with interleukin-4 (IL-4) and
granulocyte-macrophage colony-stimulating factor (GM-
CSF) in vitro.22 Murine RAW264.7 cells can be induced by
lipopolysaccharides and oxidized low-density lipoprotein to
express dendritic cell properties,23,24 and they are often
induced into dendritic-like cells.24,25 In this study, we
treated RAW264.7 cells with IL-4 and GM-CSF22,25 to model
imDC differentiation. Using this cell model, we investigated
the levels of VEGFR1, sVEGFR1, and VEGF during the dif-
ferentiation process and explored the underlying signaling
mechanisms. Our results showed that IL-4 increased the
expression of VEGFR1 and sVEGFR1 in the RAW264.7 cells,
whereas GM-CSF only increased the expression of sVEGFR1.
Blocking mitogen-activated protein kinase (p38MAPK)
signaling decreased the VEGFR1 and sVEGFR1 upregulation
that is stimulated by IL-4, but not GM-CSF. These results
demonstrated that RAW264.7 cells stimulated by IL-4
expressed high levels of sVEGFR1. Furthermore, p38MAPK
signaling was involved in this process.Methods
Cell line and cell culture
The murine monocyte/macrophage cell line RAW264.7 was
obtained from the American Type Culture Collection. Cells
were cultured in Dulbecco’s Modified Eagle’s Medium DMEM
(Gibco BRL,Gaithersburg, USA) supplemented with 10% (v/
v) heat-inactivated fetal bovine serum and 0.1 mg/mL
gentamicin at 37C in a humidified atmosphere of 95% air
and 5% carbon dioxide (CO2). To model imDC differentia-
tion, the RAW264.7 cells were plated at 4  105 cells/well
into 6-well plates and then treated with 2 mL of media
containing 20 ng/mL of recombinant mouse GM-CSF (R&D
Systems, Minneapolis, MN, USA) or 10 ng/mL of recombi-
nant mouse IL-4 (Millipore, Billerica, USA). Untreated cells
Figure 1. The RAW264.7 phenotype after IL-4 and GM-CSF
treatment. (A) The costimulatory molecules CD11c, CD80,
and CD86 are upregulated after a 3-day treatment with IL-4
(10 ng/mL) and GM-CSF (20 ng/mL). The number in the right
upper corner indicates the mean fluorescence intensity. (B) The
cell morphology under themicroscope. The cells show extended
dendritic pseudopodia. (C) The RT-PCR analysis of the VEGFR1
mRNA levels (p< 0.05). (D) TheWestern blot analysis of VEGFR1
protein levels. (E) Flow cytometry measured the VEGFR1 level
on the cell membrane. The number in the right upper corner
indicates the mean fluorescence intensity. (F) The ELISA assay
of the sVEGFR1 levels. (p < 0.05). ELISA Z enzyme-linked
immunosorbent assay; GAPDH Z glyceraldehyde-3-phosphate
dehydrogenase; GM-CSF Z granulocyte-macrophage colony-
stimulating factor; IL-4 Z interleukin-4; RT-PCR Z reverse
transcription polymerase chain reaction; sVEGFR1 Z vascular
endothelial growth factor receptor 1; VEGF Z vascular endo-
thelial growth factor; VEGFR Z vascular endothelial growth
factor receptor.
346 L. Xia et al.were used as the undifferentiated control. The cells were
harvested on Day 3 for analysis.
A subset of cells was preincubated for 1 hour with the
p38MAPK inhibitor SB203580 (cell signal technology, Boston,
USA). The cells were washed extensively and treated with
IL-4 and GM-CSF either alone or in combination. The cells
were then collected for further analysis.
Flow cytometry analysis
After treatment, the RAW264.7 cells were collected and
washed three times with cold phosphate buffered saline
(PBS). The cells were then incubated with monoclonal an-
tibodies against CD11c, CD80, CD86, and VEGFR1 at 4C forFigure 2. The expression of VEGFR1 and sVEGFR1 in
RAW264.7 cells treated with IL-4 and GM-CSF. (A) The RT-PCR
analysis of VEGFR1 mRNA levels in RAW264.7 cells stimulated
with different doses of IL-4 or GM-CSF. (B) The Western blot
analysis of VEGFR1 protein levels in cells stimulated with and
without IL-4 or GM-CSF. (C) The ELISA of the levels of sVEGFR1 in
different groups of cell culture supernatants. ELISAZ enzyme-
linked immunosorbent assay; GAPDH Z glyceraldehyde-
3-phosphate dehydrogenase; GM-CSF Z granulocyte-macro-
phage colony-stimulating factor; IL-4 Z interleukin-4;
RT-PCR Z reverse transcription polymerase chain reaction;
VEGFZ vascular endothelial growth factor; VEGFR1Z vascular
endothelial growth factor receptor 1; sVEGFZ soluble vascular
endothelial growth factor.
Mitogen-activated protein kinase signaling has an important role 34720 minutes in the dark. The cells were also stained with the
corresponding isotype-matched control antibodies. The
cells were washed three times with cold PBS and analyzed
with a flow cytometer (FACSCalibur; Becton Dickinson,
Mountain View, CA, USA). A minimum of 10,000 events per
sample were collected for analysis.Real-time polymerase chain reaction
Total RNAwas extracted from the cells using TRIZOL reagent
(Invitrogen, Carlsbad, USA) in accordance with the manu-
facturer’s instructions. The cDNA was synthesized from 1 mg
of total RNA using the ReverTra Ace qPCR RT Kit (TOYOBA,
Osaka, Japan) in a total volume of 20 mL. The PCR analysis
was performed with cDNA and the following primers: mouse
VEGFR1 (Flt1): left primer, 50-CTTTCTCAAGTGCAGAGGGG-30
and right primer, 50-TCATGTGCACAAGTTTGGGT-30; mouse
VEGF: left primer, 50-GGGACCCCTTCGTCCTCTC-30 and right
primer, 50-GTCTCCTGGGGACAGAATTAGTG-30; and mouse
glyceraldehyde-3-phosphate dehydrogenase (GAPDH): left
primer, 50-CCCACTAACATCAAATGGGG-30 and right primer, 50-Figure 3. The p38MAPK signaling in RAW264.7 cells treated with
without IL-4 (20 ng/mL) or (B) GM-CSF (20 ng/mL). Western blot a
RAW264.7 cells were pretreated with or without SB203580, and th
levels during RAW264.7 cell differentiation. (E) The RT-PCR analysis
cells stimulated with IL-4 alone or GM-CSF alone. ELISA Z enzy
3-phosphate dehydrogenase; GM-CSF Z granulocyte-macrophage
mitogen-activated protein kinase; p-p38Z phosphorylated p38 MA
VEGF Z vascular endothelial growth factor; VEGFR1 Z vascular enCCTTCCACAATGCCAAAGTT-30. The PCR parameters were as
follows: initial denaturation at 95C for 3 seconds, followed
by 40 cycles consisting of denaturation for 5 seconds at 95C,
annealing at 60C for 10 seconds, andextension at 72C for 15
seconds.
The relative mRNA level of the target genes was calcu-
lated using the comparative Ct method. The cumulative
fluorescence of each amplicon was normalized to GAPDH
amplification using the DDCt (i.e., Group 1 DCt  Group 2
DCt) method after subtracting the cumulative fluorescence
observed from the untreated group. The fold change was
calculated as 2-DDCt. Each was repeated in triplicate.Western blot analysis
Cells from 6-well plates were lysed in ice-cold radio-
immunoprecipitation assay (RIPA) lysis buffer containing
1mM phenylmethanesulfonyl fluoride (Solarbio, Beijing,
China). The supernatants were collected after centrifuga-
tion at 10,000 rpm (7500g) for 15 minutes at 4C The
protein concentration was measured using a Micro BCA TMIL-4 and GM-CSF. The RAW264.7 cells were treated (A) with and
nalysis detected the p38 and p-p38 levels. (C) For 3 days, the
en treated with IL-4 and GM-CSF. (D) ELISA assay of sVEGFR1
of VEGFR1 mRNA levels. (F) The ELISA of the sVEGFR1 levels in
me-linked immunosorbent assay; GAPDH Z glyceraldehyde-
colony-stimulating factor; IL-4 Z interleukin-4; p38 Z p38
PK; RT-PCRZ reverse transcription polymerase chain reaction;
dothelial growth factor receptor 1.
348 L. Xia et al.Protein Assay kit (Pierce, Rockford, USA). Thirty micro-
grams of protein from each sample was subjected to 6% or
12% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis, and then transferred to nitrocellulose membranes
(Invitrogen). For 2 hours, the membranes were blocked
with 5% (w/v) fat-free milk dissolved in tris-buffered saline
containing 0.05% Tween 20 (TBST). The membranes were
then incubated at room temperature for 2 hours with a
mouse VEGFR1 antibody (1:500; Abcam), a phosphorep38
MAPK (Thr180/Tyr182) antibody (1:1000; Cell Signaling), or
a p38MAPK antibody (1:1000; Cell Signaling). The mem-
branes were washed in TBST and then incubated with
horseradish peroxidase (HRP)-conjugated secondary anti-
body (1:2000, ZSGB-Bio, Beijing, China). The signals were
developed using the Immobilon Western chemiluminescent
HRP substrate (Millipore, Billerica, USA). The images were
processed and analyzed using the FluorChem system (Alpha
Innotech, Cell Biosciences, Santa Clara, USA).Enzyme-linked immunosorbent assay
Mouse sVEGFR1 (sFlt1) levels in the cell supernatants were
measured using a commercial enzyme-linked immunosor-
bent assay (ELISA) kit (R&D Systems) in accordance with the
manufacturer’s instructions. The minimum detectable dose
was 9.8 pg/mL.Statistical analysis
The data were expressed as the mean  the standard error
(SE). Data were analyzed by analysis of variance (ANOVA) or
by the Student t test. A value of p < 0.05 was considered
statistically significant.Figure 4. The VEGF expression decreases during imDC dif-
ferentiation. (A) The RT-PCR analysis of VEGF mRNA levels in
RAW cells and cytokine treatment-derived RAW264.7 cells. (B)
The RT-PCR analysis of VEGF mRNA levels in RAW264.7 cells
treated with or without different doses of IL-4 or GM-CSF. GM-
CSF Z granulocyte-macrophage colony-stimulating factor; IL-
4 Z interleukin-4; imDC Z immature dendritic cells; RT-
PCR Z reverse transcription polymerase chain reaction;
VEGF Z vascular endothelial growth factor.Results
VEGFR1 and sVEGFR1 levels increased in RAW264.7
cells treated with IL-4 and GM-CSF
The RAW264.7 cells were stimulated for 3 days with IL-4
(20 ng/mL) and GM-CSF (20 ng/mL). Flow cytometry anal-
ysis indicated the upregulated expression of the cos-
timulatory molecules CD11c, CD80, and CD86 (Fig. 1A).
Morphological changes in the cells were also observed
(Fig. 1B). The cells exhibited irregular long protrusions
similar to dendrites and increased nucleus size. These data
indicated that the differentiated cells possessed features
similar to imDCs.
The RT-PCR analysis showed that treating RAW264.7
cells with IL-4 and GM-CSF for 3 days remarkably increased
the VEGFR1 mRNA expression (Fig. 1C). Western blot anal-
ysis showed that the protein expression of VEGFR1 and
sVEGFR1 also increased (Fig. 1D). However, VEGFR1
expression on the cell membrane did not change signifi-
cantly (Fig. 1E). Thus, we speculated that sVEGFR1 within
the cells increased. To confirm this suspicion, we detected
the sVEGFR1 level in the supernatants by ELISA. The results
showed that the level of sVEGFR1 increased significantly
(p < 0.01; Fig. 1F).IL-4 and GM-CSF regulated the expression of
sVEGFR1 and VEGFR1 in RAW264.7 cells
Three different doses of recombinant murine GM-CSF
(rmGM-CSF; at 10 ng/mL, 20 ng/mL, and 50 ng/mL) and
recombinant murine IL-4 (rmIL-4; at 10 ng/mL, 20 ng/mL,
and 40 ng/mL) were applied the RAW264.7 cells to identify
their effects on the VEGFR1 and sVEGFR1 levels. Reverse
transcription polymerase chain reaction showed that the
mRNA expression of VEGFR1 was induced by IL-4, but not by
GM-CSF (Fig. 2A). However, Western blot analysis showed
that the VEGFR1 level increased when the RAW264.7 cells
were stimulated by either IL-4 or GM-CSF (Fig. 2B). Enzyme-
linked immunosorbent assay showed that IL-4 and GM-CSF
both increased the sVEGFR1 levels; however, IL-4 had a
greater effect, compared to GM-CSF (Fig. 2C). There was no
significant difference among the various doses of IL-4 or
GM-CSF. Western blot analysis showed that the VEGFR1
expression increased when RAW264.7 cells were stimulated
by IL-4 or GM-CSF (Fig. 2B). These data altogether showed
that IL-4 can promote the mRNA expression of VEGFR1 and
protein expression of sVEGFR1, whereas GM-CSF was only
able to enhance the protein expression of sVEGFR1.
Mitogen-activated protein kinase signaling has an important role 349p38MAPK signaling regulates VEGFR1 and sVEGFR1
levels in RAW264.7 cells treated with IL-4 and GM-
CSF
We then explored the signaling mechanisms involved in the
VEGFR1 and sVEGFR1 upregulation during imDC differenti-
ation. We found that p38MAPK signaling was activated when
RAW264.7 cells were treated with IL-4 or GM-CSF (Figs. 3A
and 3B). To further investigate whether p38MAPK signaling
was involved in the regulation of VEGFR1 and sVEGFR1, we
pretreated the cells with the p38MAPK inhibitor SB203580.
The VEGFR1 mRNA levels in RAW264.7 cells treated with IL-
4 and GM-CSF were significantly reduced by SB203580,
whereas the sVEGFR1 level increased (Fig. 3D). To exclude
the possibility that SB203580 may have affected the cells
stimulated by IL-4 or by GM-CSF, the RAW264.7 cells were
pretreated with SB203580 alone (Fig. 3E). The sVEGFR1
level was reduced in the cells stimulated by IL-4, but was
increased slightly in the cells stimulated by GM-CSF
(Fig. 3F). These data collectively showed that IL-4 medi-
ated VEGFR1 and sVEGFR1 levels during RAW264.7 cell
differentiation in a p38MAPK signaling-dependent manner.
VEGF expression decreased during the
differentiation of RAW264.7 cells treated with IL-4
and GM-CSF
The VEGF mRNA expression induced by IL-4 and GM-CSF
decreased in RAW264.7 cells (Fig. 4A). However, when the
cells were treated by IL-4 alone or GM-CSF alone, the VEGFFigure 5. The proposed mechanism by which IL-4 induces the exp
RAW264.7 cells. The binding of IL-4 to surface receptors on RAW264
downstream processes and activates the transcription of VEGFR1
stimulated, and the splicing of VEGFR1 to sVEGFR1 is increased. IL
kinase; p-p38Z phosphorylated p38MAPK; RT-PCRZ reverse transc
endothelial growth factor receptor 1; VEGFR1 Z vascular endothemRNA levels were not significantly different at different
doses of IL-4 or GM-CSF (Fig. 4B).
Discussion
Soluble VEGFR1 is the most important factor that antag-
onizes the proangiogenic effects of VEGF. Dendritic cells
produce high levels of sVEGFR1 and exhibit antiangiogenic
properties.19e21,26e28 In this study, we demonstrated that
sVEGFR1 levels increased (Fig. 1F) but VEGF decreased
(Fig. 4A) when RAW264.7 cells were stimulated by IL-4 and
GM-CSF, which suggests that their antiangiogenic proper-
ties increase during development. To exclude the indi-
vidual contribution of IL-4 and GM-CSF to the expression
of the VEGFR1 and sVEGFR1, the RAW264.7 cells were
treated with different doses of IL-4 alone and GM-CSF
alone. We found that IL-4 induced VEGFR1 mRNA expres-
sion in the RAW264.7 cells and that IL-4 and GM-CSF both
increased sVEGFR1 levels in monocytes. Furthermore, IL-4
had a greater effect on the production of sVEGFR1,
compared to GM-CSF in RAW264.7 cells, whereas IL-4 and
GM-CSF both had no significant effect on VEGF mRNA
expression.
The p38MAPK signaling pathway has an important role in
the response to extracellular signals such as growth factors,
mitogens, and cellular stress. The p38MAPKs are often
described as stress-activated protein kinases (SAPKs)
because they are primarily activated by extracellular
stresses and cytokines. Therefore, their role in inflamma-
tion has been extensively investigated.29e32 p38 MARKression of VEGFR1 and sVEGFR1 in cytokine treatment-derived
.7 cells activates p38MAPK signaling, which then mediates the
in the nucleus. The translation of VEGFR1 is consequently
-4 Z interleukin-4; p38MAPK Z p38 mitogen-activated protein
ription polymerase chain reaction; sVEGFR1Z soluble vascular
lial growth factor receptor 1.
350 L. Xia et al.signaling is important for the IL-4-induced production of
several cytokines.33,34 In this study, we observed increased
levels of phosphorylated p38MAPK (p-p38) in RAW264.7
cells stimulated by IL-4 and GM-CSF. The p38MAPK inhibitor
SB203580 abolished the upregulation of VEGFR1 mRNA and
sVEGFR1 levels induced by IL-4 in RAW264.7 cells. In addi-
tion, pretreatment with SB203580 decreased the VEGFR1
mRNA expression when the RAW264.7 cells were treated
with GM-CSF (Fig. 3E). Studies have indicated that the
phosphatidylinositol 3-kinase (PI-3K), c-Jun N-terminal ki-
nase (JNK), and JAnus kinase (JAK) pathways are respon-
sible for the production of sVEGFR1 in monocytes
stimulated by GM-CSF.28,35e37
There was also no report to illustrate that SB203580 can
increase sVEGFR1 in RAW264.7 cells treated with GM-CSF
and IL-4. However, SB203580 can activate extracellular
signal-regulated kinases (ERKs) and JNK in primary cul-
tures of human hepatocytes,38 and can stimulate SAPK/
JNK and PI-3K pathways in the lens,39 they were attrib-
utable to the cross-talk between divergent signaling cas-
cades and pathways. A similar situation may take place in
SB203580-preincubated RAW264.7 cells treated with GM-
CSF with or without IL-4. What is more interesting is that
the sVEGFR1 level in SB203580-preincubated RAW264.7
cells treated with GM-CSF and IL-4 increase more signifi-
cantly than the sVEGFR1 level in SB203580-preincubated
RAW264.7 cells treated with GM-CSF alone. We specu-
lated that IL-4 may amplify the cross-talk of the pathways
in the process. This should be investigated further in more
detail.
Vascular endothelial growth factor inhibits DC matu-
ration.40,41 In this study, we found that the VEGF mRNA
levels were lower during RAW264.7 differentiation.
Furthermore, the VEGF expression remained unchanged
when RAW264.7 cells were treated with IL-4 and GM-CSF,
which indicates that cytokine treatment-derived
RAW264.7 cells have antiangiogenic properties because
of the increased level of sVEGFR1 and the unchanged level
of VEGF.
Based on our data, we proposed the model, shown in
Fig. 5, to explain the upregulation of VEGFR1 and sVEGFR1
during the process of RAW264.7 cells treated with cyto-
kines. The binding of IL-4 to surface receptors on RAW264.7
cells activates p38MAPK signaling, which then mediates the
downstream processes and activates the transcription of
VEGFR1 in the nucleus. The translation of VEGFR1 is
consequently stimulated and the splicing of VEGFR1 to
sVEGFR1 is increased.
In summary, we showed for the first time that IL-4
promotes VEGFR1 mRNA transcription and sVEGFR1 pro-
duction in monocytes via the p38MAPK pathway.
Granulocyte-macrophage colony-stimulating factor
induced sVEGFR1 production, but it was independent of
p38MAPK signaling and is less potent than IL-4. These data
and the model help explain the role of imDCs in angio-
genesis and provide valuable information on treatment
strategies for diseases such as cancer and inflammation.Conflicts of interest
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